Calamos Wealth Management
VRTX icon

Calamos Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Calamos Wealth Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$655K Buy
1,252
+144
+13% +$73.7K 0.02% 286
2026
Q2 		$550K Sell
1,108
-726
-40% -$322K 0.02% 296
2026
Q1 		$819K Buy
1,834
+1,186
+183% +$553K 0.03% 233
2025
Q4 		$294K Buy
+648
New +$279K 0.01% 368
2021
Q3 		– Sell
-1,976
Closed -$398K – 322
2021
Q2 		$398K Sell
1,976
-22,226
-92% -$4.65M 0.03% 252
2021
Q1 		$5.2M Buy
24,202
+439
+2% +$96.4K 0.43% 67
2020
Q4 		$5.62M Buy
23,763
+1,137
+5% +$261K 0.51% 59
2020
Q3 		$6.16M Sell
22,626
-565
-2% -$156K 0.7% 38
2020
Q2 		$6.73M Buy
23,191
+644
+3% +$175K 0.84% 24
2020
Q1 		$5.36M Buy
+22,547
New +$5.17M 0.82% 31

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $704B AUM 26.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.84T AUM 33.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

Calamos Wealth Management's VRTX Position: Q3 2026 in Review

Calamos Wealth Management increased its Vertex Pharmaceuticals (VRTX) stake by 13% in Q3 2026, buying an estimated $73.7K and bringing the position to 1,252 shares worth $655K. The position accounts for 0.02% of the portfolio, ranked #286.

Calamos Wealth Management first reported a position in VRTX in Q1 2020 and has held it in 10 quarters since. The position peaked at $6.73M in Q2 2020. 1,556 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Calamos Wealth Management held 1,252 shares of Vertex Pharmaceuticals worth $655K as of Q3 2026.
  • Calamos Wealth Management bought 144 Vertex Pharmaceuticals shares in Q3 2026, an estimated $73.7K.
  • Vertex Pharmaceuticals made up 0.02% of Calamos Wealth Management's portfolio in Q3 2026, its #286 holding.
  • Calamos Wealth Management first reported a position in Vertex Pharmaceuticals in Q1 2020 and has held it in 10 quarters since.
  • Calamos Wealth Management's Vertex Pharmaceuticals position peaked at $6.73M in Q2 2020.
  • 1,556 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Calamos Wealth Management's 13F filing for Q3 2026, filed 2 Nov 2026.